Get started
BRISTOLMYERSDRN EDBRISTOLMYERSDRN EDBRISTOLMYERSDRN ED

BRISTOLMYERSDRN ED

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals Bonds

BMYB34 chart


Full chart

Key facts today


Bristol-Myers Squibb's Camzyos trial for hypertrophic cardiomyopathy missed key endpoints, showing no significant difference from placebo. Shares fell 2% in after-hours trading.
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪606.60 B‬ BRL
Dividend yield (indicated)
3.31%
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.02 BRL
Net income (FY)
‪−48.24 B‬ BRL
Revenue (FY)
‪260.38 B‬ BRL
Shares float
—
Beta (1Y)
−0.59

About Bristol-Myers Squibb Company


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Christopher S. Boerner
Website
bms.com
Headquarters
Princeton
Founded
1933
ISIN
BRBMYBBDR000
FIGI
BBG0025NPDT2
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BMYB34 news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

BMYB34 highest yielding bonds


US110122DS4
BRIST.MYERS 20/50
Yield to maturity
7.59%
Maturity date
Nov 13, 2050
C
BMY4560589
Celgene Corporation 4.35% 15-NOV-2047
Yield to maturity
7.04%
Maturity date
Nov 15, 2047
US110122DR6
BRIST.MYERS 20/40
Yield to maturity
6.81%
Maturity date
Nov 13, 2040
US110122DW5
BRIST.MYERS 22/52
Yield to maturity
6.80%
Maturity date
Mar 15, 2052
US110122DX3
BRIST.MYERS 22/62
Yield to maturity
6.80%
Maturity date
Mar 15, 2062
BMY3883364
Bristol-Myers Squibb Company 3.25% 01-AUG-2042
Yield to maturity
6.75%
Maturity date
Aug 1, 2042
US110122DV7
BRIST.MYERS 22/42
Yield to maturity
6.56%
Maturity date
Mar 15, 2042
BMY.GC
Bristol-Myers Squibb Company 6.875% 01-AUG-2097
Yield to maturity
6.55%
Maturity date
Aug 1, 2097
BMY5009254
Bristol-Myers Squibb Company 4.25% 26-OCT-2049
Yield to maturity
6.49%
Maturity date
Oct 26, 2049
C
BMY4036425
Celgene Corporation 5.25% 15-AUG-2043
Yield to maturity
6.40%
Maturity date
Aug 15, 2043
BMY5009251
Bristol-Myers Squibb Company 4.35% 15-NOV-2047
Yield to maturity
6.39%
Maturity date
Nov 15, 2047

See all BMYB34 bonds 

Sparks


Curated watchlists where BMYB34 is featured.

See all sparks 


Check out other big names from the same industry as BMYB34.